SCHEMBL1634316

SCHEMBL1634316

NS(=O)(=O)c1ccc(Nc2ncc3cccc(-c4ccc(CN5CCOCC5)cc4)c3n2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TBK1 Q9UHD2 3/20 0.57
▸ CSF1R P07333 2/20 0.57
▸ TYK2 P29597 2/20 0.57
▸ NTRK1 P04629 2/20 0.57
▸ NUAK1 O60285 1/20 0.57
▸ STK16 O75716 1/20 0.57
▸ CSNK2A2 P19784 1/20 0.57
▸ AAK1 Q2M2I8 1/20 0.57
▸ ULK3 Q6PHR2 1/20 0.57
▸ BMP2K Q9NSY1 1/20 0.57
▸ JAK2 O60674 7/20 0.55
▸ JAK3 P52333 5/20 0.55
▸ PTK2 Q05397 4/20 0.55
▸ ULK2 Q8IYT8 1/20 0.54
▸ IKBKE Q14164 1/20 0.54
▸ MAPK10 P53779 3/20 0.52
▸ JUN P05412 2/20 0.50
▸ MAPK8 P45983 2/20 0.50
▸ CA12 O43570 2/20 0.47
▸ CA1 P00915 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1634505 0.91 TBK1 (0.55) TBK1CSF1RTYK2NTRK1NUAK1
SCHEMBL1632397 0.85 TBK1 (0.57) TBK1CSF1RTYK2NTRK1NUAK1
SCHEMBL1633121 0.83 MAPK10 (0.52) TBK1CSF1RTYK2NTRK1NUAK1
SCHEMBL1633868 0.83 MAPK10 (0.57) JAK2JAK3MAPK10JUNMAPK8
SCHEMBL1632155 0.82 IKBKB (0.46) TBK1CSF1RTYK2NTRK1NUAK1
SCHEMBL18376853 0.81 JAK3 (0.58) TBK1CSF1RTYK2NTRK1NUAK1
SCHEMBL1633524 0.80 JAK2 (0.50) TBK1CSF1RTYK2NTRK1NUAK1
SCHEMBL18377062 0.80 JAK3 (0.56) TBK1CSF1RTYK2NTRK1NUAK1
SCHEMBL1631108 0.80 SMG1 (0.70) JAK2JAK3MAPK10JUNMAPK8
SCHEMBL18376798 0.80 JAK2 (0.55) JAK2JAK3PTK2AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 — — US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 — — US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 — — US disclosed
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2010-02-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION PDK1, PDK2, PDK3 TBK1 539/4885CSF1R 1629/4885TYK2 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback